货号： B-1709-1 g 产品名称： Bosutinib, Free Base 品牌： LC 规格： 1 g
B-1709 Explanation of the Bosutinib Problem and Bosutinib Isomer 1 •Bosutinib (SKI-606) is a tyrosine kinase inhibitor, more potent than imatinib. It has reached Phase II clinical trials in humans as an anti-cancer agent. •Aside from the ongoing clinical studies, bosutinib is also used extensively in biomedical research laboratories around the world, for non-human, non-veterinary studies. •Very unfortunately, an incorrect isomer of bosutinib has been sold to laboratory researchers under the name “Bosutinib” by 17 vendors, for various periods as long as several years. For extensive information about this bosutinib problem, please visit http://www.pkcpharma.com/TwoOrMoreBosutinibs.html. •LC Laboratories is one of the 17 vendors that sold the incorrect bosutinib isomer under the name “Bosutinib”, and the corresponding catalog number was B-1709. •To avoid confusion, we have permanently discontinued use of the B-1709 catalog number. All of the incorrect bosutinb isomer sold by LC Labs at any time was sold under the catalog number “B-1709” and name “Bosutinib, Free Base”. •We have now produced our own correct bosutinib and unambiguously proven its structure by X-ray crystallography. We have assigned a new catalog number, B-1788, to this correct bosutinib product. Please see that product page for extensive information, sizes and prices — Cat. No. B-1788, Bosutinib, Free Base. •We now refer to the particular incorrect bosutinib isomer erroneously sold by the 17 vendors as “Bosutinib Isomer 1”. •We have obtained unambiguous proof of the structure of Bosutinib Isomer 1 via X-ray crystallography, and we now offer this compound for sale under catalog number B-1722. Please see that product page for further information, sizes and prices — Cat. No. B-1722, Bosutinib Isomer 1, Free Base. •An 18th vendor has also sold incorrect bosutinib, specifically to the laboratory headed by Prof. Stefan Knapp. The incorrect version of bosutinib sold by this vendor has been unambiguously proven to be different from bosutinib but its actual structure has not yet been established.
B-1709 Explanation of the Bosutinib Problem and Bosutinib Isomer 1 •Bosutinib (SKI-606) is a tyrosine kinase inhibitor, more potent than imatinib. It has reached Phase II clinical trials in humans as an anti-cancer agent. •Aside from the ongoing clinical studies, bosutinib is also used extensively in biomedical research laboratories around the world, for non-human, non-veterinary studies. •Very unfortunately, an incorrect isomer of bosutinib has been sold to laboratory researchers under the name “Bosutinib” by 17 vendors, for various periods as long as several years. For extensive information about this bosutinib problem, please visit http://www.pkcpharma.com/TwoOrMoreBosutinibs.html. •LC Laboratories is one of the 17 vendors that sold the incorrect bosutinib isomer under the name “Bosutinib”, and the corresponding catalog number was B-1709. •To avoid confusion, we have permanently discontinued use of the B-1709 catalog number. All of the incorrect bosutinb isomer sold by LC Labs at any time was sold under the catalog number “B-1709” and name “Bosutinib, Free Base”. •We have now produced our own correct bosutinib and unambiguously proven its structure by X-ray crystallography. We have assigned a new catalog number, B-1788, to this correct bosutinib product. Please see that product page for extensive information, sizes and prices — Cat. No. B-1788, Bosutinib, Free Base. •We now refer to the particular incorrect bosutinib isomer erroneously sold by the 17 vendors as “Bosutinib Isomer 1”. •We have obtained unambiguous proof of the structure of Bosutinib Isomer 1 via X-ray crystallography, and we now offer this compound for sale under catalog number B-1722. Please see that product page for further information, sizes and prices — Cat. No. B-1722, Bosutinib Isomer 1, Free Base. •An 18th vendor has also sold incorrect bosutinib, specifically to the laboratory headed by Prof. Stefan Knapp. The incorrect version of bosutinib sold by this vendor has been unambiguously proven to be different from bosutinib but its actual structure has not yet been established.
货号： B-1709-2 g 产品名称： Bosutinib, Free Base 品牌： LC 规格： 2 g
B-1709 Explanation of the Bosutinib Problem and Bosutinib Isomer 1 •Bosutinib (SKI-606) is a tyrosine kinase inhibitor, more potent than imatinib. It has reached Phase II clinical trials in humans as an anti-cancer agent. •Aside from the ongoing clinical studies, bosutinib is also used extensively in biomedical research laboratories around the world, for non-human, non-veterinary studies. •Very unfortunately, an incorrect isomer of bosutinib has been sold to laboratory researchers under the name “Bosutinib” by 17 vendors, for various periods as long as several years. For extensive information about this bosutinib problem, please visit http://www.pkcpharma.com/TwoOrMoreBosutinibs.html. •LC Laboratories is one of the 17 vendors that sold the incorrect bosutinib isomer under the name “Bosutinib”, and the corresponding catalog number was B-1709. •To avoid confusion, we have permanently discontinued use of the B-1709 catalog number. All of the incorrect bosutinb isomer sold by LC Labs at any time was sold under the catalog number “B-1709” and name “Bosutinib, Free Base”. •We have now produced our own correct bosutinib and unambiguously proven its structure by X-ray crystallography. We have assigned a new catalog number, B-1788, to this correct bosutinib product. Please see that product page for extensive information, sizes and prices — Cat. No. B-1788, Bosutinib, Free Base. •We now refer to the particular incorrect bosutinib isomer erroneously sold by the 17 vendors as “Bosutinib Isomer 1”. •We have obtained unambiguous proof of the structure of Bosutinib Isomer 1 via X-ray crystallography, and we now offer this compound for sale under catalog number B-1722. Please see that product page for further information, sizes and prices — Cat. No. B-1722, Bosutinib Isomer 1, Free Base. •An 18th vendor has also sold incorrect bosutinib, specifically to the laboratory headed by Prof. Stefan Knapp. The incorrect version of bosutinib sold by this vendor has been unambiguously proven to be different from bosutinib but its actual structure has not yet been established.
B-1709 Explanation of the Bosutinib Problem and Bosutinib Isomer 1 •Bosutinib (SKI-606) is a tyrosine kinase inhibitor, more potent than imatinib. It has reached Phase II clinical trials in humans as an anti-cancer agent. •Aside from the ongoing clinical studies, bosutinib is also used extensively in biomedical research laboratories around the world, for non-human, non-veterinary studies. •Very unfortunately, an incorrect isomer of bosutinib has been sold to laboratory researchers under the name “Bosutinib” by 17 vendors, for various periods as long as several years. For extensive information about this bosutinib problem, please visit http://www.pkcpharma.com/TwoOrMoreBosutinibs.html. •LC Laboratories is one of the 17 vendors that sold the incorrect bosutinib isomer under the name “Bosutinib”, and the corresponding catalog number was B-1709. •To avoid confusion, we have permanently discontinued use of the B-1709 catalog number. All of the incorrect bosutinb isomer sold by LC Labs at any time was sold under the catalog number “B-1709” and name “Bosutinib, Free Base”. •We have now produced our own correct bosutinib and unambiguously proven its structure by X-ray crystallography. We have assigned a new catalog number, B-1788, to this correct bosutinib product. Please see that product page for extensive information, sizes and prices — Cat. No. B-1788, Bosutinib, Free Base. •We now refer to the particular incorrect bosutinib isomer erroneously sold by the 17 vendors as “Bosutinib Isomer 1”. •We have obtained unambiguous proof of the structure of Bosutinib Isomer 1 via X-ray crystallography, and we now offer this compound for sale under catalog number B-1722. Please see that product page for further information, sizes and prices — Cat. No. B-1722, Bosutinib Isomer 1, Free Base. •An 18th vendor has also sold incorrect bosutinib, specifically to the laboratory headed by Prof. Stefan Knapp. The incorrect version of bosutinib sold by this vendor has been unambiguously proven to be different from bosutinib but its actual structure has not yet been established.
B-1709 Explanation of the Bosutinib Problem and Bosutinib Isomer 1 •Bosutinib (SKI-606) is a tyrosine kinase inhibitor, more potent than imatinib. It has reached Phase II clinical trials in humans as an anti-cancer agent. •Aside from the ongoing clinical studies, bosutinib is also used extensively in biomedical research laboratories around the world, for non-human, non-veterinary studies. •Very unfortunately, an incorrect isomer of bosutinib has been sold to laboratory researchers under the name “Bosutinib” by 17 vendors, for various periods as long as several years. For extensive information about this bosutinib problem, please visit http://www.pkcpharma.com/TwoOrMoreBosutinibs.html. •LC Laboratories is one of the 17 vendors that sold the incorrect bosutinib isomer under the name “Bosutinib”, and the corresponding catalog number was B-1709. •To avoid confusion, we have permanently discontinued use of the B-1709 catalog number. All of the incorrect bosutinb isomer sold by LC Labs at any time was sold under the catalog number “B-1709” and name “Bosutinib, Free Base”. •We have now produced our own correct bosutinib and unambiguously proven its structure by X-ray crystallography. We have assigned a new catalog number, B-1788, to this correct bosutinib product. Please see that product page for extensive information, sizes and prices — Cat. No. B-1788, Bosutinib, Free Base. •We now refer to the particular incorrect bosutinib isomer erroneously sold by the 17 vendors as “Bosutinib Isomer 1”. •We have obtained unambiguous proof of the structure of Bosutinib Isomer 1 via X-ray crystallography, and we now offer this compound for sale under catalog number B-1722. Please see that product page for further information, sizes and prices — Cat. No. B-1722, Bosutinib Isomer 1, Free Base. •An 18th vendor has also sold incorrect bosutinib, specifically to the laboratory headed by Prof. Stefan Knapp. The incorrect version of bosutinib sold by this vendor has been unambiguously proven to be different from bosutinib but its actual structure has not yet been established.
B-1709 Explanation of the Bosutinib Problem and Bosutinib Isomer 1 •Bosutinib (SKI-606) is a tyrosine kinase inhibitor, more potent than imatinib. It has reached Phase II clinical trials in humans as an anti-cancer agent. •Aside from the ongoing clinical studies, bosutinib is also used extensively in biomedical research laboratories around the world, for non-human, non-veterinary studies. •Very unfortunately, an incorrect isomer of bosutinib has been sold to laboratory researchers under the name “Bosutinib” by 17 vendors, for various periods as long as several years. For extensive information about this bosutinib problem, please visit http://www.pkcpharma.com/TwoOrMoreBosutinibs.html. •LC Laboratories is one of the 17 vendors that sold the incorrect bosutinib isomer under the name “Bosutinib”, and the corresponding catalog number was B-1709. •To avoid confusion, we have permanently discontinued use of the B-1709 catalog number. All of the incorrect bosutinb isomer sold by LC Labs at any time was sold under the catalog number “B-1709” and name “Bosutinib, Free Base”. •We have now produced our own correct bosutinib and unambiguously proven its structure by X-ray crystallography. We have assigned a new catalog number, B-1788, to this correct bosutinib product. Please see that product page for extensive information, sizes and prices — Cat. No. B-1788, Bosutinib, Free Base. •We now refer to the particular incorrect bosutinib isomer erroneously sold by the 17 vendors as “Bosutinib Isomer 1”. •We have obtained unambiguous proof of the structure of Bosutinib Isomer 1 via X-ray crystallography, and we now offer this compound for sale under catalog number B-1722. Please see that product page for further information, sizes and prices — Cat. No. B-1722, Bosutinib Isomer 1, Free Base. •An 18th vendor has also sold incorrect bosutinib, specifically to the laboratory headed by Prof. Stefan Knapp. The incorrect version of bosutinib sold by this vendor has been unambiguously proven to be different from bosutinib but its actual structure has not yet been established.
B-1709 Explanation of the Bosutinib Problem and Bosutinib Isomer 1 •Bosutinib (SKI-606) is a tyrosine kinase inhibitor, more potent than imatinib. It has reached Phase II clinical trials in humans as an anti-cancer agent. •Aside from the ongoing clinical studies, bosutinib is also used extensively in biomedical research laboratories around the world, for non-human, non-veterinary studies. •Very unfortunately, an incorrect isomer of bosutinib has been sold to laboratory researchers under the name “Bosutinib” by 17 vendors, for various periods as long as several years. For extensive information about this bosutinib problem, please visit http://www.pkcpharma.com/TwoOrMoreBosutinibs.html. •LC Laboratories is one of the 17 vendors that sold the incorrect bosutinib isomer under the name “Bosutinib”, and the corresponding catalog number was B-1709. •To avoid confusion, we have permanently discontinued use of the B-1709 catalog number. All of the incorrect bosutinb isomer sold by LC Labs at any time was sold under the catalog number “B-1709” and name “Bosutinib, Free Base”. •We have now produced our own correct bosutinib and unambiguously proven its structure by X-ray crystallography. We have assigned a new catalog number, B-1788, to this correct bosutinib product. Please see that product page for extensive information, sizes and prices — Cat. No. B-1788, Bosutinib, Free Base. •We now refer to the particular incorrect bosutinib isomer erroneously sold by the 17 vendors as “Bosutinib Isomer 1”. •We have obtained unambiguous proof of the structure of Bosutinib Isomer 1 via X-ray crystallography, and we now offer this compound for sale under catalog number B-1722. Please see that product page for further information, sizes and prices — Cat. No. B-1722, Bosutinib Isomer 1, Free Base. •An 18th vendor has also sold incorrect bosutinib, specifically to the laboratory headed by Prof. Stefan Knapp. The incorrect version of bosutinib sold by this vendor has been unambiguously proven to be different from bosutinib but its actual structure has not yet been established.
Bosutinib (SKI-606) Product Overview Product Name: Bosutinib (SKI-606) Alternate Name/Synonyms: SKI-606 Description: Bosutinib (SKI-606) is a novel tyrosine kinase inhibitor. Bosutinib can overcome not only Bcr-Abl-dependent mechanisms of resistance, but also those that are Bcr-Abl-independent. It is used to treat patients with chronic myelogenous leukemia (CML) who demonstrate resistance to Imatinib or develop resistance during treatment. Peptide Sequence: N/A Appearance: White to off-white solid Formulation: N/A CAS Number: 380843-75-4 Molecular Formula: C₂₆H₂₉Cl₂N₅O₃ Molecular Weight: 530.45 Purity: ≥99% by HPLC Solubility:DMSO (30 mg/ml) or EtOH (10 mg/ml) Storage Temp.: -20°C Shipping Conditions: RT Handling: Protect from light and moisture SMILES: CN1CCN(CC1)CCCOC2=CC3=NC(=CC(=C3C=C2OC)NC4=CC(=C(C=C4Cl)Cl)OC)C#N InChi: InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-26-14-22-18(12-25(26)35-3)21(11-17(16-29)30-22)31-23-15-24(34-2)20(28)13-19(23)27/h11-15H,4-10H2,1-3H3,(H,30,31) InChi Key: ALUXPRDJABOEAG-UHFFFAOYSA-N PubChem CID: 46926609 MDL Number: MFCD07367846 USAGE: For Research Use Only! Not For Use in Humans.
Bosutinib (SKI-606) Product Overview Product Name: Bosutinib (SKI-606) Alternate Name/Synonyms: SKI-606 Description: Bosutinib (SKI-606) is a novel tyrosine kinase inhibitor. Bosutinib can overcome not only Bcr-Abl-dependent mechanisms of resistance, but also those that are Bcr-Abl-independent. It is used to treat patients with chronic myelogenous leukemia (CML) who demonstrate resistance to Imatinib or develop resistance during treatment. Peptide Sequence: N/A Appearance: White to off-white solid Formulation: N/A CAS Number: 380843-75-4 Molecular Formula: C₂₆H₂₉Cl₂N₅O₃ Molecular Weight: 530.45 Purity: ≥99% by HPLC Solubility:DMSO (30 mg/ml) or EtOH (10 mg/ml) Storage Temp.: -20°C Shipping Conditions: RT Handling: Protect from light and moisture SMILES: CN1CCN(CC1)CCCOC2=CC3=NC(=CC(=C3C=C2OC)NC4=CC(=C(C=C4Cl)Cl)OC)C#N InChi: InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-26-14-22-18(12-25(26)35-3)21(11-17(16-29)30-22)31-23-15-24(34-2)20(28)13-19(23)27/h11-15H,4-10H2,1-3H3,(H,30,31) InChi Key: ALUXPRDJABOEAG-UHFFFAOYSA-N PubChem CID: 46926609 MDL Number: MFCD07367846 USAGE: For Research Use Only! Not For Use in Humans.
Bosutinib structural isomer Description Bosutinib structural isomer differ only in the positions of the chlorines and methoxy substituents on the aniline ring. Often mistaken to be the correct structure of bosutinib. Specifications Product ID B5875 Product Name Bosutinib structural isomer Chemical Name 4-(3,5-Dichloro-4-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Formula C26H29Cl2N5O3 Formula Wt. 530.45 Melting Point 210-221 ºC
Bosutinib structural isomer Description Bosutinib structural isomer differ only in the positions of the chlorines and methoxy substituents on the aniline ring. Often mistaken to be the correct structure of bosutinib. Specifications Product ID B5875 Product Name Bosutinib structural isomer Chemical Name 4-(3,5-Dichloro-4-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Formula C26H29Cl2N5O3 Formula Wt. 530.45 Melting Point 210-221 ºC
Bosutinib structural isomer Description Bosutinib structural isomer differ only in the positions of the chlorines and methoxy substituents on the aniline ring. Often mistaken to be the correct structure of bosutinib. Specifications Product ID B5875 Product Name Bosutinib structural isomer Chemical Name 4-(3,5-Dichloro-4-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Formula C26H29Cl2N5O3 Formula Wt. 530.45 Melting Point 210-221 ºC
